Skip to main content

German drugmaker

Altana

(AAA)

received U.S. regulatory approval for its Omnaris spray for nasal allergies.

TheStreet Recommends

The Food and Drug Administration cleared the drug to treat seasonal and perennial allergic rhinitis in patients 12 years of age and older. The agency also said the drug is approvable for the treatment of children aged 2 to 11.

"With the approval of Omnaris we offer patients with allergic rhinitis an innovative treatment option," Altana said. "Omnaris will extend our ciclesonide product platform by an important new therapeutic from Altana Pharma's own research."